• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24030 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) - a health technology assessment]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Reducing mammaplasty for the treatment of patients with breast hypertrophy and chronic dorsalgia]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Reducing bilirubin-induced neurological dysfunction in premature newborns: additional use of bilirubin:albumin ratio in the treatment of hyperbilirubinemia]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Redesigning maternal education: proposal for a framework to draw up an education programme for health and effective birth preparation focused on the needs of women]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Rectal cancer investigation, treatment and follow-up algorithm]
2013     Andalusian Health Technology Assessment Area (AETSA) [Recommendations for the proper use of inverted shoulder prosthesis]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Recommendations for the appropriate use of vitamin D tests and supplements in the general population]
1997     Basque Office for Health Technology Assessment (OSTEBA) [Recommendations for appropriate use of magnetic resonance]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Recombinant follicle-stimulating hormone (rFSH) versus human chorionic gonadotropin (uhMG) for assisted reproductive techniques]
2008     Committee for New Health Technology Assessment (CNHTA) [Recombinant blood coagulation Factor VIII activity test by chromogenic assay]
2016     Gesundheit Osterreich GmbH (GOeG) [Recent evidence on drug therapy of psychological and behavioral symptoms in Alzheimer's dementia]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Recent advances in gene therapy]
2015     Haute Autorite de sante (HAS) [Reassessment of the eligibility criteria of transcather aortic valve implantation by transcutaneous blood or by transapical delivery]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Real-time magnetic resonance imaging (MRI)-guided radiation therapy]
2021     Canary Health Service [Real-time continuous glucose monitoring device for gestational diabetes]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Real time intraoperative magnetic resonance imaging monitoring]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Real time high resolution MR image guidance during irradiation]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Real time continuous glucose monitoring systems]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Reablement for seniors experience a loss of autonomy]
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Re-orientation of the Austrian parent-child preventive care programme. Part XII: Economic evaluation of selected screenings during pregnancy]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [RCT of point of care C-reactive protein test and enhanced communication skills for managing acute cough due to lower respiratory tract infection in general practice: cost effectiveness and effect on diagnostic testing, antibiotic prescribing and recovery]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Addendum to Commission A19-59]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (neuromyelitis optica spectrum disorder [NMOSD]) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (generalized myasthenia gravis) - Benefit assessment according to § 35a SGB V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (atypical haemolytic uraemic syndrome) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab - Benefit assessment according to §35a Social Code Book V]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Rational use of self-monitoring of blood glucose in type 1 diabetes]
2015     Haute Autorite de sante (HAS) [Rating trabecular bridging micro stents and their act of implanting]
2015     Haute Autorite de sante (HAS) [Rare visceral surgery procedures by laparoscopy]
2011     Institut national d'excellence en sante et en services sociaux (INESSS) [Rare disease management: experiences from abroad]
2005     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rapid-acting insulin analogues in the treatment of diabetes mellitus type 2]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rapid-acting insulin analogues in the treatment of diabetes mellitus type 1]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rapid-acting insulin analogues in children and adolescents with diabetes mellitus type 1 - follow-up commission]
2012     Andalusian Health Technology Assessment Area (AETSA) [Rapid tests for methicillin resistant Staphylococcus aureus. Carrier screening. Executive summary]
2010     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Rapid systematic review on radiotherapy in lung cancer]
2014     Andalusian Health Technology Assessment Area (AETSA) [Rapid review. Gender dysphoria. Diagnosis, treatment and health outcomes]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid review: alternatives to timolol for the treatment of glaucoma]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: mitigation strategies to counter the shortage of sublingual nitroglycerin sprays and tablets]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: intravesical treatment for bladder cancer]
2017     Andalusian Health Technology Assessment Area (AETSA) [Rapid response: Effectiveness and safety of hyperthermia in combination with radiation therapy and/or chemotherapy in the treatment of breast, cervix and rectum cancer]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: description of specialized geriatric services and their organizational and clinical components in Canada (outside Quebec) and internationally]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: Cervical cancer: transition from from Pap test screening to HPV testing]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Rapid on-site evaluations of cytological punctures]
2008     Committee for New Health Technology Assessment (CNHTA) [Rapid isoniazid and rifampicin resistance test(sequencing)]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of the artery protection system Embol-X]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of rituximabe in treating B-cell non-hodgkin's lymphoma, low-grade CD 20]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of rituximab for rheumatoid arthritis]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of radiofrequency ablation in the surgical treatment of atrial fibrillation]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of malignant melanoma]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of malignant lymphoma]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of head and neck cancers]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of esophageal cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of colon and rectal cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of breast cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of polyglycolic polymerized matrix artery graft]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of paliperidone for treating schizophrenia]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of natriuretic peptides for diagnosing cardiac insufficiency in patients with acute dyspnea]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of lithium dilution systems for monitoring cardiac output: comparison with available alternatives]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of infliximab for treatment of psoriasis]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of everolimus to prevent renal transplant rejection]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of capecitabine for metastatic breast cancer]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of capecitabine for Dukes'C colorectal cancer (stage III)]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Bortezomib in treating refractory multiple myeloma]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of basal action recombinant insulin, analogous to human insulin, (glargine and determir) for treating type 1 diabetes mellitus]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Alteplase (rt-PA) in the cerebral vascular ischemic accident]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of alpha thyrotropin for diagnosis and treatment of thyroid cancer]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of a disposable multi-dose injection pen pre-filled with human growth hormone (somatropin) solution for injection (Norditropin Nordilet)]
2008     Belgian Health Care Knowledge Centre (KCE) [Rapid assessment of a selection of new treatments for prostate cancer and benign prostate hypertrophy]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Ranibizumab, bevacizumab and aflibercept for age-related macular degeneration]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [Randomized trial on the effects of a psychogeriatric diagnostic day hospital]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Randomized trial of timing of delivery in early preterm fetal growth restriction based on early and late fetal Doppler venous changes versus cardiotocography. Acronym TRUFFLE = Trial of Umbilical and Fetal Flow in Europe]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Ramucirumab for advanced gastric or gastroesophageal junction cancer]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (NSCLC, combination with erlotinib) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (hepatocellular carcinoma) - Addendum to Commission A19-73]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (colorectal cancer) - Addendum to Commission A16-10]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab - benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Raltegravir for the treatment of human immunodeficiency virus infection]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radium-223-dichloride - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radium-223 dichloride (mCRPC) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2012     Andalusian Health Technology Assessment Area (AETSA) [Radiosurgery and stereotactic body radiation therapy. Efficacy, safety and efficiency in primary lung cancer and pulmonary oligometastases]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radionuclide therapy - 90Yttrium and 177Lutetium somatostatin analogues for the treatment of inoperable neuroendocrine tumors]
2000     Finnish Office for Health Care Technology Assessment (Finohta) [Radiology in Central Finland - a regional operational model for the 2000s]
2009     Committee for New Health Technology Assessment (CNHTA) [Radiofrequency(RF) ablation of high grade dysplastic nodule of the liver]
2009     Committee for New Health Technology Assessment (CNHTA) [Radiofrequency(RF) ablation of hepatocellular adenoma]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency-assisted surgery in inferior turbinate hypertrophy]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Radiofrequency tonsil reduction]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency percutaneous nucleoplasty in disc disorders]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radiofrequency energy treatment for organic erectile dysfunction]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Radiofrequency echographic multi-spectrometry for bone mineral density assessment]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Radiofrequency denervation for chronic lumbar or cervical spine pain]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Radiofrequency catheter ablation using in-silico modelling in atrial fibrillation]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of tumours of the lung and mediastinal lymph nodes]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of tumors of the urogenital tract (renal cell carcinoma, prostate cancer, uterine leiomyoma)]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of primary tumors of the gastrointestinal tract (colorectal and pancreatic cancer)]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency ablation of parathyroid glands]